Profil
Rolf Magnus Björsne is currently the Chief Executive Officer at AstraZeneca BioVentureHub AB, Chairman at Termino C 2915 AB, and Director at SwedenBIO Service AB. He previously worked as a Director at Beactica Therapeutics AB from 2014 to 2018 and as an Independent Director at Isofol Medical AB from 2018 to 2023.
Björsne holds a doctorate from the University of Stockholm and an MBA from Henley Management College.
Postes actifs de Rolf Magnus Björsne
| Sociétés | Poste | Début |
|---|---|---|
SwedenBIO Service AB
SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services Provides educational services | Directeur/Membre du Conseil | - |
Termino C 2915 AB | Président | - |
AstraZeneca BioVentureHub AB | Directeur Général | - |
Anciens postes connus de Rolf Magnus Björsne
| Sociétés | Poste | Fin |
|---|---|---|
| ISOFOL MEDICAL AB | Directeur/Membre du Conseil | 01/02/2023 |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Operates as a drug discovery company | Directeur/Membre du Conseil | 01/01/2018 |
Formation de Rolf Magnus Björsne
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
University of Stockholm
University of Stockholm Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Henley Management College
Henley Management College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beactica Therapeutics AB
Beactica Therapeutics AB Medical DistributorsDistribution Services Operates as a drug discovery company | Distribution Services |
SwedenBIO Service AB
SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services Provides educational services | Commercial Services |
Isofol Medical AB
Isofol Medical AB Pharmaceuticals: MajorHealth Technology Provides novel folate-based pharmaceutical products | Health Technology |
Termino C 2915 AB | |
AstraZeneca BioVentureHub AB |
















